Editorial
One and Done — Single-Dose Zoledronic Acid in Early-Stage Breast Cancer
NEJM Evidence · 26.05.2026 · 5 (6)
DOI: 10.1056/evide2600083 ↗Kurz gefasst
Editorial in der Zeitschrift NEJM Evidence, erschienen am 26.05.2026. Verfasst von Neelima Vidula. Beteiligte Einrichtung: Massachusetts General Hospital, Harvard Medical School, Boston, MA. Die Arbeit nennt 10 Literaturangaben.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Autor:innen und Institutionen
- Massachusetts General Hospital, Harvard Medical School, Boston, MA.
Zitieren
APA
Vidula, N. (2026). One and Done — Single-Dose Zoledronic Acid in Early-Stage Breast Cancer. NEJM Evidence, 5(6). https://doi.org/10.1056/evide2600083
Vancouver
Vidula N. One and Done — Single-Dose Zoledronic Acid in Early-Stage Breast Cancer. NEJM Evidence. 2026;5(6). doi:10.1056/evide2600083
BibTeX
@article{Vidula2026,
author = {Vidula, Neelima},
title = {One and Done — Single-Dose Zoledronic Acid in Early-Stage Breast Cancer},
journal = {NEJM Evidence},
year = {2026},
volume = {5},
number = {6},
doi = {10.1056/evide2600083}
}
EUVIMED